According to CoinMeta, Citibank analysts stated that Sanofi's best-selling drug dupixent may face competition in the coming years. The analysts mentioned that AstraZeneca's tozorakimab, Pfizer's tilrekimig, as well as AbbVie's zumilokibart and apogee's zumilokibart could all pose a threat to the sales of dupixent. dupixent (jointly developed by Sanofi and Regeneron Pharmaceuticals) contributed to Sanofi's third-quarter performance exceeding expectations. However, according to Citibank's forecast, the growth rate of dupixent sales is expected to slow down from this year's estimated 32% to 12% by 2027, and the pricing advantage may no longer drive growth after 2027. Citibank has raised its target price for Sanofi from 78 euros to 93 euros.